Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland.
PLoS One. 2009 Dec 4;4(12):e8154. doi: 10.1371/journal.pone.0008154.
Neuroblastoma, a cancer derived from precursor cells of the sympathetic nervous system, is a major cause of childhood cancer related deaths. The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors.
We applied MYCN chromatin immunoprecipitation to microarrays (ChIP-chip) using MYCN amplified/non-amplified cell lines as well as a conditional knockdown cell line to determine the distribution of MYCN binding sites within all annotated promoter regions.
Assessment of E-box usage within consistently positive MYCN binding sites revealed a predominance for the CATGTG motif (p<0.0016), with significant enrichment of additional motifs CATTTG, CATCTG, CAACTG in the MYCN amplified state. For cell lines over-expressing MYCN, gene ontology analysis revealed enrichment for the binding of MYCN at promoter regions of numerous molecular functional groups including DNA helicases and mRNA transcriptional regulation. In order to evaluate MYCN binding with respect to other genomic features, we determined the methylation status of all annotated CpG islands and promoter sequences using methylated DNA immunoprecipitation (MeDIP). The integration of MYCN ChIP-chip and MeDIP data revealed a highly significant positive correlation between MYCN binding and DNA hypermethylation. This association was also detected in regions of hemizygous loss, indicating that the observed association occurs on the same homologue. In summary, these findings suggest that MYCN binding occurs more commonly at CATGTG as opposed to the classic CACGTG E-box motif, and that disease associated over expression of MYCN leads to aberrant binding to additional weaker affinity E-box motifs in neuroblastoma. The co-localization of MYCN binding and DNA hypermethylation further supports the dual role of MYCN, namely that of a classical transcription factor affecting the activity of individual genes, and that of a mediator of global chromatin structure.
神经母细胞瘤是一种起源于交感神经系统前体细胞的癌症,是导致儿童癌症相关死亡的主要原因。在这种疾病中,预后不良的最重要的单一预测指标是 MYCN 的基因组扩增,MYCN 是致癌转录因子家族的一个成员。
我们使用 MYCN 扩增/非扩增细胞系以及条件性敲低细胞系应用 MYCN 染色质免疫沉淀到微阵列(ChIP-chip),以确定 MYCN 结合位点在所有注释启动子区域内的分布。
在一致阳性的 MYCN 结合位点内评估 E 盒的使用情况表明,CATGTG 基序占主导地位(p<0.0016),在 MYCN 扩增状态下,CATTTG、CATCTG、CAACTG 等额外基序的富集显著。对于过度表达 MYCN 的细胞系,基因本体分析显示,在包括 DNA 解旋酶和 mRNA 转录调节在内的许多分子功能组的启动子区域,MYCN 的结合得到了富集。为了评估 MYCN 结合与其他基因组特征的关系,我们使用甲基化 DNA 免疫沉淀(MeDIP)来确定所有注释的 CpG 岛和启动子序列的甲基化状态。MYCN ChIP-chip 和 MeDIP 数据的整合显示,MYCN 结合与 DNA 超甲基化之间存在高度显著的正相关。在杂合性丢失的区域也检测到了这种关联,这表明观察到的关联发生在相同的同源物上。总之,这些发现表明,MYCN 结合更常见于 CATGTG,而不是经典的 CACGTG E 盒基序,并且与疾病相关的 MYCN 过度表达导致神经母细胞瘤中额外较弱亲和力的 E 盒基序的异常结合。MYCN 结合和 DNA 超甲基化的共定位进一步支持了 MYCN 的双重作用,即作为影响单个基因活性的经典转录因子,以及作为全局染色质结构的介导物。